OBJECTIVE: To assess the accuracy of the cervical phosphorylated insulin-like growth factor binding protein-1 (phIGFBP-1) test to predict @entity600 in @entity1 with and without symptoms of @entity3152 through the use of formal methods for systematic reviews and metaanalytic techniques. DATA SOURCES: PubMed, Embase, Cinahl, Lilacs, and Medion (all from inception to June 30, 2015), reference lists, conference proceedings, and Google scholar. STUDY ELIGIBILITY CRITERIA: Cohort or cross-sectional studies that reported on the predictive accuracy of the cervical phIGFBP-1 test for @entity600 . STUDY APPRAISAL AND SYNTHESIS METHODS: Two reviewers independently selected studies, assessed the risk of bias, and extracted the data. Summary receiver-operating characteristic curves, pooled sensitivities and specificities, and summary likelihood ratios were generated. RESULTS: Forty-three studies met the inclusion criteria, of which 15 provided data on asymptomatic @entity1 (n  = 6583) and 34 on @entity1 with an episode of @entity3152 (n  = 3620). Among asymptomatic @entity1 , the predictive accuracy of the cervical phIGFBP-1 test for @entity600 at <37, <34, and <32 weeks of gestation was minimal, with pooled sensitivities and specificities and summary positive and negative likelihood ratios ranging from 14% to 47%, 76% to 93%, 1.5 to 4.4, and 0.6 to 1.0, respectively. Among @entity1 with an episode of @entity3152 , the test had a low predictive performance for delivery within 7 and 14 days of testing, and @entity600 at <34 and <37 weeks of gestation with pooled sensitivities and specificities and summary positive and negative likelihood ratios that varied between 60% and 68%, 77% and 81%, 2.7 and 3.5, and 0.4 and 0.5, respectively. A negative test result in @entity1 with an episode of @entity3152 had a low to moderate accuracy to identify @entity1 who are not at risk for delivering within the next 48 hours (summary negative likelihood ratio of 0.28 in all @entity1 and 0.23 in @entity1 with singleton gestations). CONCLUSION: Cervical phIGFBP-1 has the potential utility to identify @entity1 with an episode of @entity3152 who will not deliver within 48 hours. However, its overall predictive ability for the identification of symptomatic and asymptomatic @entity1 at risk for @entity600 is limited.

Cervical phosphorylated insulin-like growth factor binding protein-1 test for the prediction of XXXX : a systematic review and metaanalysis.

@entity1 :: ('9606', 'Species') :: ['patients', 'women'] @entity3152 :: ('MESH:D007752', 'Disease') :: ['preterm labor'] @entity600 :: ('MESH:D000014', 'Disease') :: ['preterm birth']
@entity600 :: (MESH:D000014,Disease) :: ['preterm birth']
